Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 27 | 2025 | 800 | 7.230 |
Why?
|
| Kidney Failure, Chronic | 4 | 2024 | 924 | 1.430 |
Why?
|
| Fatigue | 4 | 2023 | 196 | 1.080 |
Why?
|
| Sertraline | 4 | 2020 | 44 | 1.070 |
Why?
|
| Antidepressive Agents | 4 | 2025 | 316 | 0.980 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2023 | 1357 | 0.970 |
Why?
|
| Glomerular Filtration Rate | 5 | 2025 | 539 | 0.960 |
Why?
|
| Hypertension | 3 | 2022 | 1335 | 0.880 |
Why?
|
| Forearm | 1 | 2024 | 38 | 0.880 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2024 | 93 | 0.820 |
Why?
|
| Diuretics | 2 | 2022 | 154 | 0.810 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2023 | 63 | 0.790 |
Why?
|
| Angioedema | 1 | 2023 | 22 | 0.790 |
Why?
|
| Veterans | 3 | 2023 | 1742 | 0.790 |
Why?
|
| Renal Dialysis | 4 | 2024 | 936 | 0.770 |
Why?
|
| Renal Replacement Therapy | 2 | 2023 | 158 | 0.750 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 491 | 0.750 |
Why?
|
| Hyperkalemia | 1 | 2023 | 69 | 0.730 |
Why?
|
| Depression | 4 | 2025 | 1295 | 0.710 |
Why?
|
| Acute Kidney Injury | 3 | 2023 | 664 | 0.680 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 259 | 0.660 |
Why?
|
| Antihypertensive Agents | 2 | 2023 | 416 | 0.590 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 111 | 0.550 |
Why?
|
| Quality of Life | 4 | 2023 | 2030 | 0.520 |
Why?
|
| Humans | 39 | 2025 | 127455 | 0.520 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 444 | 0.520 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2017 | 107 | 0.510 |
Why?
|
| Vascular Calcification | 1 | 2017 | 65 | 0.500 |
Why?
|
| Blood Pressure | 2 | 2021 | 1338 | 0.480 |
Why?
|
| Troponin T | 1 | 2017 | 248 | 0.470 |
Why?
|
| Cardiovascular Diseases | 4 | 2025 | 2038 | 0.470 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 322 | 0.440 |
Why?
|
| Atherosclerosis | 2 | 2021 | 930 | 0.430 |
Why?
|
| Peptide Fragments | 1 | 2017 | 762 | 0.400 |
Why?
|
| Heart Failure | 2 | 2023 | 2288 | 0.390 |
Why?
|
| Proteinuria | 2 | 2024 | 105 | 0.380 |
Why?
|
| Sex Workers | 1 | 2012 | 5 | 0.380 |
Why?
|
| Urinalysis | 2 | 2024 | 73 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 1274 | 0.380 |
Why?
|
| Inflammation | 1 | 2019 | 1434 | 0.380 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2023 | 214 | 0.370 |
Why?
|
| Contact Tracing | 1 | 2012 | 54 | 0.360 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 1438 | 0.350 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2012 | 98 | 0.350 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 735 | 0.340 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 850 | 0.330 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 112 | 0.320 |
Why?
|
| Obesity | 1 | 2021 | 2338 | 0.320 |
Why?
|
| Disease Progression | 3 | 2023 | 2125 | 0.320 |
Why?
|
| Middle Aged | 11 | 2025 | 27867 | 0.300 |
Why?
|
| Creatinine | 4 | 2025 | 385 | 0.290 |
Why?
|
| Female | 15 | 2025 | 68733 | 0.270 |
Why?
|
| Aged | 9 | 2025 | 20494 | 0.260 |
Why?
|
| Male | 13 | 2025 | 62861 | 0.260 |
Why?
|
| Renin-Angiotensin System | 2 | 2023 | 103 | 0.240 |
Why?
|
| Hypoglycemic Agents | 3 | 2021 | 456 | 0.240 |
Why?
|
| Biomarkers | 3 | 2020 | 3252 | 0.230 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 1371 | 0.230 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2023 | 134 | 0.230 |
Why?
|
| Survival Analysis | 2 | 2019 | 1501 | 0.220 |
Why?
|
| Adult | 9 | 2025 | 30579 | 0.220 |
Why?
|
| Prognosis | 3 | 2019 | 4803 | 0.220 |
Why?
|
| Specific Gravity | 1 | 2024 | 4 | 0.220 |
Why?
|
| Erythrocyte Transfusion | 1 | 2025 | 136 | 0.220 |
Why?
|
| Reagent Strips | 1 | 2024 | 11 | 0.220 |
Why?
|
| Arm | 1 | 2024 | 72 | 0.210 |
Why?
|
| Postoperative Care | 1 | 2025 | 307 | 0.200 |
Why?
|
| Pituitary-Adrenal System | 1 | 2023 | 38 | 0.200 |
Why?
|
| Surgical Procedures, Operative | 1 | 2025 | 227 | 0.200 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2023 | 44 | 0.200 |
Why?
|
| Prescriptions | 1 | 2023 | 44 | 0.190 |
Why?
|
| Thiazides | 1 | 2022 | 5 | 0.190 |
Why?
|
| Chlorthalidone | 1 | 2022 | 24 | 0.190 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2022 | 31 | 0.190 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 28 | 0.190 |
Why?
|
| Steroids | 1 | 2023 | 158 | 0.190 |
Why?
|
| Potassium | 1 | 2023 | 265 | 0.190 |
Why?
|
| Retrospective Studies | 4 | 2024 | 17076 | 0.190 |
Why?
|
| Cystatin C | 1 | 2022 | 69 | 0.180 |
Why?
|
| Anemia | 1 | 2025 | 341 | 0.180 |
Why?
|
| Albuminuria | 2 | 2025 | 104 | 0.180 |
Why?
|
| Hematuria | 1 | 2022 | 49 | 0.180 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2021 | 18 | 0.180 |
Why?
|
| Hypotension, Orthostatic | 1 | 2021 | 20 | 0.180 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6716 | 0.170 |
Why?
|
| Glucosides | 1 | 2021 | 53 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 2999 | 0.160 |
Why?
|
| Benzhydryl Compounds | 1 | 2021 | 74 | 0.160 |
Why?
|
| Risk Factors | 5 | 2025 | 10631 | 0.150 |
Why?
|
| Body Mass Index | 2 | 2022 | 1659 | 0.150 |
Why?
|
| Risk Management | 1 | 2018 | 65 | 0.130 |
Why?
|
| United States | 5 | 2025 | 11399 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2025 | 3594 | 0.130 |
Why?
|
| Aspirin | 1 | 2018 | 209 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 453 | 0.120 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 393 | 0.120 |
Why?
|
| Pandemics | 1 | 2023 | 1141 | 0.120 |
Why?
|
| Self Report | 1 | 2019 | 538 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2022 | 2239 | 0.120 |
Why?
|
| Cause of Death | 1 | 2017 | 487 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2022 | 4987 | 0.110 |
Why?
|
| Coronary Angiography | 1 | 2017 | 452 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2019 | 12580 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1055 | 0.110 |
Why?
|
| Sex Factors | 1 | 2018 | 1315 | 0.110 |
Why?
|
| Disease Management | 1 | 2018 | 544 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2025 | 3073 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 873 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1207 | 0.100 |
Why?
|
| Comorbidity | 1 | 2018 | 1563 | 0.100 |
Why?
|
| Guatemala | 1 | 2012 | 64 | 0.090 |
Why?
|
| Sexual Partners | 1 | 2012 | 79 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 2814 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 124 | 0.090 |
Why?
|
| Kidney | 1 | 2017 | 1283 | 0.080 |
Why?
|
| Patient Preference | 1 | 2012 | 140 | 0.080 |
Why?
|
| Texas | 1 | 2017 | 3565 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2019 | 6249 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2012 | 562 | 0.070 |
Why?
|
| Time Factors | 1 | 2017 | 6169 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3720 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2025 | 236 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2025 | 313 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2025 | 305 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 92 | 0.050 |
Why?
|
| Hospitalization | 2 | 2022 | 1880 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2022 | 268 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2022 | 303 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2025 | 1047 | 0.040 |
Why?
|
| Veterans Health | 1 | 2021 | 171 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 428 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7423 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2022 | 692 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2025 | 979 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 424 | 0.030 |
Why?
|
| Infant | 1 | 2012 | 12806 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2022 | 779 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3694 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1602 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 3263 | 0.030 |
Why?
|